Displaying 31 - 45 of 653
David Paterson is a newly appointed Professor of Infectious Diseases at the University of Queensland, and Consultant Infectious Diseases Physician and Microbiologist at the Royal Brisbane and Women's Hospital. His prior appointment was Director of the Antibiotic Management Program at the University of Pittsburgh Medical Center. He is the author of more than 100 peer-reviewed publications in the field of infectious diseases and clinical microbiology. His specific areas of interest are in antibiotic resistance in Gram negative bacilli and optimisation of antimicrobial use in the critically ill and the immunocompromised. He was the winner of the American Society for Microbiology's Merck Irving Siegal Award awarded at ICAAC 2000 and has been an advisor to the Clinical and Laboratory Standards Institute (CLSI).
Professor of Infectious Diseases at the University of Queensland
|David W. Denning||
David W. Denning
Professor of Infectious Diseases in Global Health and Consultant in Infectious Diseases and Medical Mycology, Wythenshawe Hospital and University of Manchester and President of the Global Action Fund for Fungal Infections.
Graduate of Guy's Hospital, University of London, 1980. Clinical training in internal medicine, infectious diseases, microbiology, paediatrics and haematology in London, Glasgow and California (1980-1990). Research training at the MRC Clinical Research Centre, Harrow, UK (1985-87) and Stanford University, California, USA (1987-1990). Granted a personal chair by Manchester University in 2005.
My clinical interests are in fungal diseases, immunocompromised patients and complex hospital infection problems.
My research interests relate to antifungal susceptibility testing and resistance, pathogenesis of invasive aspergillosis, clinical studies of antifungal agents, Aspergillusgenomics and the burden of fungal infections globally and in different countries.
In addition to continuing clinical practice and research, I was instrumental in starting a biotechnology company called F2G. F2G has identified several new promising antifungal drug candidates , one of which is shortly to be studied in human volunteers. I retain a very small number of F2G shares, but no longer consult for it.
In 2006, I founded Myconostica, a molecular diagnostics spin-out of The University of Manchester. Myconostica developed and commercialised rapid real-time molecular diagnostic tests for Aspergillus and Pneumocystis, before being acquired by Lab21 in May 2011. IÂ advise Trinity Biotech (who now handle Myconostica products) on clinical aspects of fungal diagnosis as a consultantI also advise T2 Biosystems (diagnostics), GSK (Vaccines) and give talks on behalf of Astellas, Pfizer and Gilead. In 2013,I became President of the Global Action Fund for Fungal infections.
Key contributions to the literature:
David W. Denning FRCP FRCPath FIDSA FMedSci
|Jens C. Frisvad||
Jens C. Frisvad
Professor, dr. techn., Ph.D.
Industrial mycology, Biodiversity, Extralites.
Recent key contributions to the literature:
Technical University of Denmark
Tel +45 45 25 26 26